Dijon

• Efficacy and safety of bezafibrate 400 mg and bezafibrate 200 mg as adjunctive treatments in patients with primary biliary cholangitis and n … Recruiting
  2023-504086-23-00 5 2025-03-27 Subjects with PBC with a non-optimal response to UDCA.
• Clinical trial evaluating the efficacy of pemigatinib for the treatment of patients with solid tumours with an alteration of the gene FGFR Recruiting
  2024-512729-10-00 4 2025-03-27 Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rea
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting
  2024-515566-13-00 5 2025-03-19 Diffuse Large B-Cell Lymphoma (DLBCL)
• First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a ran … Recruiting
  2023-503326-39-00 5 2025-03-06 Synchronous oligometastatic non-small cell lung cancer (NSCLC)
• Capecitabine plus pembrolizumab in patients with triple negative breast cancer after chemoimmunotherapy and surgery Recruiting
  2023-505291-30-01 4 2025-03-06 Triple Negative Breast Cancer with residual disease after neoadjuvant
• Chimiothérapie à base de bevacizumab adaptée à la pharmacocinétique du bevacizumab en 1ère ligne de traitement du cancer colorectal métastat … Recruiting
  2023-507873-16-00 11 2025-03-04 1st line treatment for unresectable metastatic colorectal cancer
• Clinical trial of molnupiravir (MK-4482) in adults who have COVID-19 and are not hospitalized, who are at high risk for serious illness from … Recruiting
  2023-507227-36-00 5 2025-02-21 SARS-CoV-2 (COVID-19) infection
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag … Recruiting
  2023-509787-15-00 5 2025-02-17 Patients with localised prostate cancer and high-risk features of rela
• A phase II, multicenter, open-label study evaluating Glofitamab in combination with Venetoclax plus Zanubrutinib or Venetoclax alone in subj … Recruiting
  2023-506706-40-00 10 2025-02-11 Mantle-Cell Lymphoma
• Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction Recruiting
  2023-508798-94-00 5 2025-02-11 Heart failure
• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
• Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca … Recruiting
  2022-502352-31-00 5 2025-02-10 Colorectal Cancer (CRC)
• PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatel … Recruiting
  2024-510772-20-00 4 2025-02-06 Rectal cancer locally advanced with microsatellite unstable or mismatc
• DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMI … Recruiting
  2024-513475-41-00 5 2025-02-03 Multiple Sclerosis
• EWALL-PH-03: An open label, 2-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib plus Chemotherapy with Imatinib … Recruiting
  2023-505330-95-01 4 2025-01-30 Blood cancer
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 4 2025-01-27 Crohn's disease
• Surgical treatment of large incisional hernia with botulinum toxin A injection: a double-blind randomized controlled trial Recruiting
  2023-504554-35-00 5 2025-01-17 incisional hernia
• Dose individualization of chemotherapy in patients with gastrointestinal cancers lacking a specific liver enzyme Recruiting
  2023-509963-25-00 4 2025-01-17 Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer
• SUPPRESS. Prophylactic frequent premature ventricular complexeS sUPPression on left ventriculaR function impairmEnt in aSymptomatic patientS Recruiting
  2024-516372-14-00 11 2025-01-13 Asymptomatic Patients with frequent PVCs and normal LVEF
• EvER-ILD 3 : Evaluation of Efficacy and safety of Rituximab and mycophenolate mofetil combination in patients with Interstitial Lung Disease … Recruiting
  2023-510507-21-00 10 2025-01-08 Intersitial lung disease related to systemic sclerosis
• Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting
  2023-509811-98-00 4 2025-01-07 Patients with HER2-positive locally advanced inoperable or metastatic
• Interest of post-operative chemotherapy in patients with localized uterine leiomyosarcoma suspected to have a high-risk of relapse based on … Recruiting
  2023-506350-21-00 4 2025-01-06 Localized, resected, FIGO stage I (2018 classification), uterine leiom
• BLOCKADE OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN PATIENTS WITH ARVD.BRAVE Recruiting
  2023-505048-20-00 4 2024-12-20 Arrhythmogenic right ventricular dysplasia

Showing 265–288 of 813 trials